Zenas BioPharma, Inc.
ZBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $5 | $50 | $0 |
| % Growth | -90% | – | – |
| Cost of Goods Sold | $139 | $0 | $62 |
| Gross Profit | -$134 | $50 | -$62 |
| % Margin | -2,682.8% | 100% | – |
| R&D Expenses | $139 | $60 | $63 |
| G&A Expenses | $29 | $17 | $13 |
| SG&A Expenses | $30 | $17 | $14 |
| Sales & Mktg Exp. | $1 | $0 | $1 |
| Other Operating Expenses | -$139 | $10 | -$62 |
| Operating Expenses | $30 | $87 | $15 |
| Operating Income | -$164 | -$37 | -$76 |
| % Margin | -3,277.8% | -74.3% | – |
| Other Income/Exp. Net | $7 | $0 | -$43 |
| Pre-Tax Income | -$157 | -$37 | -$119 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$157 | -$37 | -$119 |
| % Margin | -3,139.8% | -74.2% | – |
| EPS | -3.76 | -0.97 | -3.11 |
| % Growth | -287.6% | 68.8% | – |
| EPS Diluted | -3.76 | -0.97 | -3.11 |
| Weighted Avg Shares Out | 42 | 38 | 38 |
| Weighted Avg Shares Out Dil | 42 | 38 | 38 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$164 | -$27 | -$75 |
| % Margin | -3,275% | -54.1% | – |